- AdventHealth
In a remarkable season of medical innovation, physicians with the AdventHealth Heart, Lung and Vascular Institute performed three groundbreaking procedures, marking significant advancements in patient care. These “firsts” represent a leap forward in the treatment of cardiovascular conditions for residents of Central Florida.
“Being first means we can offer our community access to leading treatments that may not be available elsewhere,” said Gordon Wesley vice president of the institute, who emphasized the significance of being at the forefront of medical and technological advancements. “This not only enhances patient outcomes but also attracts top talent and fosters clinical richness in the area, ultimately increasing access to care for our communities.”
On March 13, Dr. Nipun Arora, an interventional cardiologist, along with colleagues Dr. Rodrigo Do Lago and Dr. Jorge Suarez, performed the first-in-Central Florida Navitor Transcatheter Aortic Valve Replacement (TAVR) procedure. This minimally invasive procedure replaces the need for open-heart surgery, ultimately reducing recovery time. It treats aortic valve stenosis by replacing a narrow valve in the heart with a new one. This new technique not only ensures successful valve replacement but also holds promise for future heart surgeries.
The following day, on March 14, Dr. Naushad Shaik, electrophysiologist and EP medical director, led the inaugural Pulse Field Ablation (PFA) procedure in Central Florida. PFA is a promising new treatment for atrial fibrillation (AFib) patients. It’s a safer, more efficient approach than traditional methods that use heat, which can inadvertently damage surrounding tissues. PFA delivers short-duration electrical pulses to the cardiac tissue. The energy from the pulses kills the cells in the tissue causing the irregular heart rate and rhythm, therefore restoring the heart to a more normal condition.
Rounding out the trifecta, on May 21, Dr. Mark Steiner, an interventional cardiologist, conducted the first commercial renal denervation procedure in Central Florida. This innovative treatment targets patients with high blood pressure who do not respond to medication alone. High blood pressure affects nearly half of all Americans and can lead to serious health complications if left uncontrolled. This procedure uses radiofrequency on nerves in the kidney, which can cause hypertension. This offers a minimally invasive solution for managing a prevalent condition that can improve the quality of life for countless patients.
“It is very rare we are able to do three, new technologically advanced procedures within weeks of each other,” said Wesley. “This is a testament to the collaboration with many on our team as well as the innovation happening at AdventHealth. We’ve become a destination for both experts and partners to leverage technology and knowledge simultaneously to advance patient care for our communities.”
Wesley adds that part of advancing patient care also means expanding care into new areas of the community to include an extension of the structural heart program at AdventHealth Celebration to include the TAVR program this month.
Recent News
AdventHealth Cancer Institute Advances the Use of CAR T-Cell Therapy for Multiple Myeloma
CAR-T therapies have emerged as new treatment options for certain types of cancer through a one-time infusion that can lead to long-lasting remission.
AdventHealth Graduate Medical Education Program Celebrates 50 Years
Growing from a family practice residency to 24 accredited programs, AdventHealth’s Graduate Medical Education (GME) program celebrates 50 years.
New Clinical Trial Explores Digital Intervention for Apathy in Late-life Depression
Afflicting 30-50% of patients with late-life depression, apathy is a challenging psychiatric syndrome in older adulthood that can result in lack of motivation leading to poor self-care, physical...
AdventHealth Performs Central Florida’s First Liver Transplant for Unresectable Colorectal Liver Metastases
In June 2025, AdventHealth Abdominal Transplant Surgeon and Surgical Oncologist Ryan Day, MD, worked with a multidisciplinary team to perform Central Florida’s first liver transplant for unresectable...
AdventHealth Neuroscience Institute First in Florida to be Recognized as a GammaTile Center of Excellence
GammaTile is the first and only tile-based radiation therapy for the treatment of
operable brain tumors. The AdventHealth Neuroscience Institute began performing GammaTile procedures in 2021 and was...
An AdventHealth Collaboration Explores the Impact of Microgravity and Electrical Stimulation on Muscle Cell Health in Space
Using a muscle lab-on-chip model aboard the International Space Station (ISS), AdventHealth Translational Research Institute’s Dr. Paul Coen has been working with a multidisciplinary team from the...
AdventHealth Neuroscience Institute Among First in U.S. to Offer Phase IIa Clinical Trial of Troculeucel for Moderate Alzheimer’s Disease
While most clinical trials for Alzheimer’s disease have focused on patients with early or mild cognitive impairment, roughly 30% of those with Alzheimer’s have moderate stage disease for which there...
AdventHealth Translational Research Institute Selected as Clinical Site for National Study of Muscle, Mobility and Aging (SOMMA)
Under the leadership of Scientific Director and Principal Investigator Bret H. Goodpaster, PhD, the AdventHealth Translational Research Institute (TRI) is now enrolling men and women 70 years of age...
AdventHealth Neuroscience Institute Administers First Dose of Investigative NK Cell Therapy to Person with Alzheimer’s Disease
Under a single compassionate use Investigational New Drug (IND) authorization cleared by the U.S. Food and Drug Administration (FDA), the AdventHealth Neuroscience Institute worked with NKGen Biotech...
New Study Published in the New England Journal of Medicine Shows the Addition of Regional Nodal Irradiation Does Not Decrease Rate of Invasive Breast Cancer Recurrence in Patients with Negative Axillary Nodes Following Neoadjuvant Chemotherapy
Findings of the phase III, multicenter, randomized NSABP B-51-RTOG 1304 clinical trial were recently published in the New England Journal of Medicine with AdventHealth Cancer Institute’s Dr. Mamounas...
AdventHealth Study Exploring the Use of MR-Guided Focused Ultrasound (MRgFUS) to Disrupt the Blood-Brain Barrier for Treatment of Alzheimer’s Disease
Under the leadership of Dr. Valeria Baldivieso and Dr. Chandan Reddy, the AdventHealth Research Institute is the first and only site in Orlando offering the Exablate Blood-Brain Barrier (BBB)...
AdventHealth Research Institute Offers Phase II Clinical Trial of Etanercept for Treatment of Blast-Induced Tinnitus
Approximately 1 billion people throughout the world suffer from tinnitus (ringing in the ears), and it is the number one disability of those who serve in the U.S. military. The condition can disrupt...